ストックスクリーナーアプリを入手
13.60
2.51%
-0.35
アフターアワーズ：
13.55
-0.05
-0.37%
前日終値:
$13.95
開ける：
$13.86
24時間の取引高:
119.83K
Relative Volume:
0.68
時価総額：
$333.27M
収益：
$31,000
当期純損益:
$-246.41M
株価収益率:
-1.0677
EPS:
-12.7377
ネットキャッシュフロー:
$-134.42M
1週間 パフォーマンス:
-5.09%
1か月 パフォーマンス:
+2.10%
6か月 パフォーマンス:
-46.41%
1年 パフォーマンス:
+28.54%
1日の値動き範囲:
$13.39
$13.93
1週間の範囲:
$13.39
$15.52
52週間の値動き範囲:
$10.49
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
名前
Lyell Immunopharma Inc
セクター
電話
650 695-0677
住所
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
13.60 | 341.85M | 31,000 | -246.41M | -134.42M | -12.74 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Needham | Buy |
| 2026-03-09 | 開始されました | Citizens | Mkt Outperform |
| 2025-12-09 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-06-27 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-11-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-17 | 開始されました | H.C. Wainwright | Buy |
| 2021-07-12 | 開始されました | BofA Securities | Buy |
| 2021-07-12 | 開始されました | Goldman | Buy |
| 2021-07-12 | 開始されました | JP Morgan | Overweight |
| 2021-07-12 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Lyell Immunopharma Inc (LYEL) 最新ニュース
Lyell Immunopharma (LYEL): Foresite funds and Tananbaum report 2.7% ownership - Stock Titan
Citizens reiterates Lyell Immunopharma stock rating on pipeline progress By Investing.com - Investing.com Canada
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Lyell Immunopharma (LYEL) Slides 4.77% to $14.17 as Biotech Risk Appetite FadesTriple Top - dars.gov.et
Lyell Immunopharma VP Bulis sells $8,905 of common stock By Investing.com - Investing.com Nigeria
Lyell Immunopharma VP Veronica Sanchez Bulis Sells 621 Shares for Tax Withholding on August 10, 2026 - Kalkine Media
Lyell Immunopharma COO Stephen J. Hill Sells Shares to Cover Tax Withholding on RSU Settlement - Kalkine Media
Lyell Immunopharma (LYEL) CSO auto-sells shares to cover RSU tax withholding - Stock Titan
Lyell Immunopharma VP Bulis sells $8,905 of common stock - Investing.com
Lyell Immunopharma (LYEL) VP auto-sells 621 shares to cover RSU taxes - Stock Titan
Lyell Immunopharma (LYEL) COO auto-sells 89 shares for RSU tax withholding - Stock Titan
Lyell Immunopharma (LYEL) CEO sells shares to cover RSU tax withholding - Stock Titan
Renaissance Technologies LLC Buys 76,921 Shares of Lyell Immunopharma, Inc. $LYEL - marketbeat.com
Lyell Immunopharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Lyell Immunopharma earnings beat by $0.22, revenue fell short of estimates - Investing.com Canada
Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - webull.com
Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a shareEarnings Preview - TradingView
Lyell Immunopharma: Q2 Earnings Snapshot - AOL.com
Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingView
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - manilatimes.net
BRIEF-Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million - TradingView
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus - MarketBeat
Stifel Initiates Lyell Immunopharma(LYEL.US) With Buy Rating, Announces Target Price $36 - Moomoo
LYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36 - Bitget
Stifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy - Investing.com South Africa
LYEL Q2'26 Earnings: revenue estimate is 4.60K USD - TradingView
Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Price to book forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL - TradingView
Form 4 Lyell Immunopharma Inc For: 27 July By Investing.com - Investing.com Nigeria
Lyell Immunopharma, Inc. (LYEL) holder pays broker with 44,000 shares - Stock Titan
Broker commission transfer of 38,500 shares in Lyell Immunopharma (LYEL) - Stock Titan
Lyell Immunopharma Inc (LYEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lyell Immunopharma Inc (LYEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lyell Immunopharma Inc (LYEL) Cash Flow - TradingKey
Lyell Immunopharma Inc (LYEL) Institutional Confidence - TradingKey
Lyell Immunopharma Inc (LYEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LYEL|Lyell Immunopharma Inc|Price:12.950|Chg%:+0.320 - TradingKey
TradingKey - TradingKey
Lyell Immunopharma Inc (LYEL) Balance Sheet - TradingKey
LYEL|Lyell Immunopharma Inc|Price:12.615|Chg%:-0.165 - TradingKey
Lyell Immunopharma, Inc. Revenue Breakdown – NASDAQ:LYEL - TradingView
Lyell Immunopharma Inc (LYEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lyell Immunopharma Inc (LYEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
B. Riley Securities Initiates Lyell Immunopharma(LYEL.US) With Buy Rating, Announces Target Price $44 - Moomoo
LYEL Initiates Coverage by B. Riley Securities -- Price Target A - GuruFocus
Stifel initiates Lyell Immunopharma stock with buy, $44 target - Investing.com India
Lyell Immunopharma, Inc. SEC Filing (Jul 22, 2026) - Stock Titan
Stifel initiates Lyell Immunopharma stock with buy, $44 target By Investing.com - Investing.com Canada
Form 4 Lyell Immunopharma Inc For: 21 July By Investing.com - Investing.com Nigeria
Lyell Immunopharma Inc (LYEL) 財務データ
収益
当期純利益
現金流量
EPS
Lyell Immunopharma Inc (LYEL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lee Gary K. | Chief Scientific Officer |
Aug 10 '26 |
Sale |
14.34 |
131 |
1,879 |
17,677 |
| Hill Stephen J. | Chief Operating Officer |
Aug 10 '26 |
Sale |
14.34 |
89 |
1,276 |
17,805 |
| Seely Lynn | President and CEO |
Aug 10 '26 |
Sale |
14.34 |
390 |
5,593 |
73,488 |
| Innovative Cellular Therapeuti | 10% Owner |
Jul 17 '26 |
Sale |
13.70 |
10 |
137 |
2,857,480 |
| Innovative Cellular Therapeuti | 10% Owner |
Jul 16 '26 |
Sale |
13.73 |
10 |
137 |
2,857,490 |
| Seely Lynn | President and CEO |
May 11 '26 |
Sale |
18.91 |
388 |
7,337 |
73,878 |
| Lee Gary K. | Chief Scientific Officer |
May 11 '26 |
Sale |
18.92 |
130 |
2,460 |
17,808 |
| Hill Stephen J. | Chief Operating Officer |
May 11 '26 |
Sale |
18.92 |
89 |
1,684 |
17,894 |
| Bulis Veronica Sanchez | VP, Corporate Controller |
May 11 '26 |
Sale |
18.91 |
217 |
4,103 |
15,420 |
| Shook David | Chief Medical Officer |
Jun 10 '26 |
Sale |
12.64 |
1,977 |
24,989 |
20,923 |
2.20%
0.07%
大文字化:
|
ボリューム (24 時間):